The global injection pen market is projected to grow from USD 46.09 billion in 2026 to USD 84.8 billion by 2035, a 7.02% compound annual growth rate, according to a new forecast from Precedence Research. The report, published August 10, 2026, also estimates that North America held 43% of the market in 2025 and that the U.S. market alone was valued at USD 13.88 billion in 2025, on track to reach USD 27.98 billion by 2035. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
For the peptide therapy and research peptide industry, the forecast matters because injection pens are the primary delivery format for a growing class of peptide-based medicines, including GLP-1 receptor agonists for diabetes and weight management. As clinics, telehealth platforms, and compounding pharmacies scale peptide services, demand for reliable, patient-friendly injection devices is becoming a supply-chain and business-model consideration, not just a device-industry statistic.
What the Precedence Research Forecast Says
Precedence Research estimates the global injection pen market at USD 46.09 billion in 2026 and anticipates it will reach around USD 84.8 billion by 2035, expanding at a CAGR of 7.02% from 2026 to 2035. The firm reports that North America led the global market with the largest share of 43% in 2025, while Asia Pacific is projected to grow at the fastest CAGR during the forecast period.
By product type, the disposable segment dominated the global injection pen market in 2025, while the reusable segment is projected to grow at a solid CAGR. By therapy, the diabetes segment dominated the global market in 2025, and the cancer segment is expanding at a significant CAGR. By end user, the homecare segment dominated in 2025, with hospitals and diagnostic centers expected to be the fastest-growing segment during the forecast period.
The U.S. market was evaluated at USD 13.88 billion in 2025 and is predicted to be worth around USD 27.98 billion by 2035, rising at a CAGR of 7.26% from 2026 to 2035. These figures are forecasts, not audited market results, and the report does not disclose its base-year methodology or segment definitions in the publicly available summary.
Key Numbers at a Glance
| Metric | Value | Source |
|---|---|---|
| Global injection pen market, 2026 | USD 46.09 billion | Precedence Research |
| Global injection pen market, 2035 | USD 84.8 billion | Precedence Research |
| Global CAGR, 2026–2035 | 7.02% | Precedence Research |
| North America market share, 2025 | 43% | Precedence Research |
| U.S. market, 2025 | USD 13.88 billion | Precedence Research |
| U.S. market, 2035 | USD 27.98 billion | Precedence Research |
| U.S. CAGR, 2026–2035 | 7.26% | Precedence Research |
| People living with diabetes, global | ~537 million now; 783 million by 2045 | International Diabetes Federation, as cited |
| Insulin pen export shipments, June 2024–May 2025 | 843 shipments, +69% year-on-year | Volza, as cited |
Why This Matters for Peptide Therapy
The forecast’s center of gravity is diabetes, the therapy segment that dominated the market in 2025. According to the International Diabetes Federation, as cited in the report, around 537 million people are living with diabetes today, and that number is expected to reach 783 million by 2045. GLP-1 peptide drugs such as semaglutide and tirzepatide are central to diabetes and weight-management care, and most are delivered by pen or autoinjector. The Precedence Research figures therefore describe, at least in part, the device layer of the peptide drug economy.
For peptide therapy clinics, telemedicine operators, and medical spas, the practical implication is that pen-format supply is a strategic input. Clinics that prescribe or dispense GLP-1 therapies depend on device availability, patient training, and cold-chain handling. The report cites self-administration convenience and reduced cost as demand drivers, but these are qualitative assertions; the report does not quantify cost savings or adherence improvements. Industry observers note that device shortages or format changes can ripple through clinic operations faster than drug shortages, because patients are trained on a specific pen and reimbursement may be tied to a specific product configuration.
The report also flags a May 2025 decision by Novo Nordisk to use its Flextouch pen for injection of its weight-loss drug in the U.S., as it does elsewhere. That is a single-company example without volume data, but it illustrates how device-format choices by large peptide manufacturers can shift demand across the pen supply chain.
Supply Chain and Manufacturing Context
Injection pens sit at the end of a long peptide supply chain: peptide API synthesis, formulation into vials or dual-chamber cartridges, fill-finish, device assembly, labeling, and cold-chain distribution. The report’s trade data, attributed to Volza, shows 843 insulin pen shipments exported worldwide from June 2024 to May 2025, a 69% year-on-year change, with the U.S., Malaysia, and Vietnam as leading exporters. Shipment counts are not revenue, and the report does not reconcile them with market value, but they indicate active cross-border device trade.
Regulatory compliance is a cited restraint. The report notes that companies that do not follow prescribed standards, such as U.S. FDA requirements and biocompatibility testing, can face regulatory issues. For peptide businesses sourcing devices or cartridge-based formats, this reinforces the need for documented quality controls. A certificate of analysis for a peptide API does not establish finished-product quality, sterility, or regulatory approval, and the same logic applies to device components and container-closure systems.
PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates. For operators tracking device and container trends, resources such as peptidescm can help map suppliers and component categories, though any sourcing decision still requires independent verification of specifications and compliance.
Research and Market Context
The report cites broader disease burden data to support demand. The World Health Organization, as cited, says cardiovascular diseases account for 32% of global deaths. The International Agency for Research on Cancer, also as cited, estimates global cancer cases will grow 47% from 2020 to 2040, reaching 28.4 million cases in 2040. These figures describe patient populations, not injection pen adoption rates, and the report does not model conversion from prevalence to device use.
The report also describes AI integration into injection devices as supporting glucose assessment, personalized dosing, and remote monitoring. This claim is presented qualitatively, without named sources or quantified outcomes, and should be treated as an early-stage trend rather than established clinical benefit. Similarly, the report’s assertion that sustainability concerns favor reusable pens sits in tension with its finding that disposable pens dominated in 2025; the report does not reconcile the two.
What Comes Next
Several questions remain open. The forecast does not disclose how much of projected pen growth depends on GLP-1 peptide drugs versus insulin or other biologics. It does not quantify the impact of oral alternatives or other delivery formats. And it does not provide volume data, so value growth could reflect pricing as much as unit expansion.
For peptide therapy stakeholders, the watch items are concrete: device-format decisions by major peptide manufacturers, FDA compliance expectations for device components, export and import trends for pens and cartridges, and clinic-level training and cold-chain practices. The Precedence Research forecast is a directional signal, not a guarantee, and the peptide industry’s device layer will likely evolve alongside drug pipelines and reimbursement policy.
FAQ
What is the projected size of the injection pen market?
Precedence Research estimates the global market at USD 46.09 billion in 2026, rising to USD 84.8 billion by 2035 at a 7.02% CAGR.
How large is the U.S. injection pen market?
The U.S. market was valued at USD 13.88 billion in 2025 and is forecast to reach USD 27.98 billion by 2035, according to Precedence Research.
Why does the injection pen market matter for peptide therapy?
Many peptide drugs, including GLP-1 therapies, are delivered by pen or autoinjector, so device supply and format choices affect clinics, telehealth platforms, and patients.
Are injection pens FDA-approved?
Device and drug-device combination approval status varies by product. Approval must be verified for the specific product and indication; a market forecast does not establish regulatory status.
Comments